Clinical Trials Directory

Trials / Unknown

UnknownNCT03610529

CardioSenseSystem Compared Study Regarding Efficacy and Safety in the Monitoring of ECG

CardioSenseSystem Compared to Philips Telemetry System Regarding Efficacy and Safety in the Monitoring of ECG

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Novosense AB · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, controlled, comparative clinical trial of a new ECG monitoring system CardioSenseSystem prior CE marking. The aim of the study is to demonstrate that the CardioSenseSystem's cable-free ECG monitoring system (investigational device) is equivalent or better than traditional and accepted industry standard for cable-based ECG monitoring system (control device). In this study accepted industry standard is Philips Intellivue. In order to investigate this, the study will measure ECG monitoring interruptions, management time and alarm performance. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be using both the investigational device and the control device simultaneous for measuring data loss, management time and alarm function up to 24 hours.

Detailed description

A prospective, controlled and comparative clinical trial before CE marking of a new ECG monitoring system CardioSenseSystem. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be monitored by both the investigational device and the control device for measuring data loss, management time and alarm function up to 24 hours. The duration of the study is estimated to 4 months. CardioSenseSystem is designed to provide wireless high-quality ECG monitoring. The system developed by Novosense AB consists of three components: the CardioPatch, the Novosense Base Station and the Back-End System. The CardioPatch is a wireless sensor capable to record and transmit ECG data. The CardioPatch send ECG data to the Novosense Base Station, which is the receiving unit. The Back-End System is used for presentation, storage and processing of ECG information. The CardioPatch sensor is applied to the body with an adhesive in the same way as a traditional ECG electrode. In contrast, the CardioPatch is a fully integrated unit containing electrodes, ECG amplifier and a radio transmitter. Novosense's wireless ECG sensors, CardioPatch, transmits the ECG signal 24 hours to the Novosense Base Station receiver.

Conditions

Interventions

TypeNameDescription
DEVICECardioSenseSystemCardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
DEVICEPhilips IntellivuePhilips Intellivue in an established ECG monitoring system used at the clinical investigational device.

Timeline

Start date
2020-09-01
Primary completion
2020-12-01
Completion
2020-12-30
First posted
2018-08-01
Last updated
2020-09-11

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT03610529. Inclusion in this directory is not an endorsement.

CardioSenseSystem Compared Study Regarding Efficacy and Safety in the Monitoring of ECG (NCT03610529) · Clinical Trials Directory